Evidence map›Paper›PMID 28376230›Full record

Trial reportJournal of the National Cancer Institute2017

Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.

Carl E Allen, Theodore W Laetsch, Rajen Mody, Meredith S Irwin, Megan S Lim, Peter C Adamson, Nita L Seibel, D Williams Parsons, Y Jae Cho, Katherine Janeway and 1 more

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the National Cancer Institute, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 3 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 3 syntheses or guidelines pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Carl E AllenTexas Children's Cancer Center, Texas Children's Hospital, Houston, TX, USA.
Theodore W LaetschDivision of Pediatric Hematology-Oncology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Rajen ModyDivision of Pediatric Hematology-Oncology, Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA.
Meredith S IrwinDepartment of Pediatrics, Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada.
Megan S LimDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Hospital of the University of Pennsylvania and Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Peter C AdamsonDivision of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Nita L SeibelDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA.
D Williams ParsonsTexas Children's Cancer Center, Texas Children's Hospital, Houston, TX, USA.
Y Jae ChoDivision of Pediatric Neurology, Doernbecher Children's Hospital, Portland, OR, USA.
Katherine JanewayDepartment of Pediatric Oncology, Dana-Farber/Boston Children's Cancer Center and Blood Disorder Center, Boston, MA, USA.
Pediatric MATCH Target and Agent Prioritization Committee
Children's Cancer Center · USBaylor College of Medicine · USTexas Children's Hospital · US

Funding

Tissue ResourceP50CA126752 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Leonid S Metelitsa · 2007 to 2026
$51.4M
ERK control of Dendritic Cell Differentiation, Homeostasis and DiseaseR01CA154947 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CARL E ALLEN, MIRIAM MERAD · 2011 to 2026
$7.0M
NCI NIH HHS P50 CA126752NCI NIH HHS R01 CA154947
6 · The paper itself

Abstract

Over the past decades, outcomes for children with cancer have improved dramatically through serial clinical trials based in large measure on dose intensification of cytotoxic chemotherapy for children with high-risk malignancies. Progress made through such dose intensification, in general, is no longer yielding further improvements in outcome. With the revolution in sequencing technologies and rapid development of drugs that block specific proteins and pathways, there is now an opportunity to improve outcomes for pediatric cancer patients through mutation-based targeted therapeutic strategies. The Children's Oncology Group (COG), in partnership with the National Cancer Institute (NCI), is planning a trial entitled the COG-NCI Pediatric Molecular Analysis for Therapeutic Choice (Pediatric MATCH) protocol utilizing an umbrella design. This protocol will have centralized infrastructure and will consist of a biomarker profiling protocol and multiple single-arm phase II trials of targeted therapies. Pediatric patients with recurrent or refractory solid tumors, lymphomas, or histiocytoses with measurable disease will be eligible. The Pediatric MATCH Target and Agent Prioritization (TAP) committee includes membership representing COG disease committees, the Food and Drug Administration, and the NCI. The TAP Committee systematically reviewed target and agent pairs for inclusion in the Pediatric MATCH trial. Fifteen drug-target pairs were reviewed by the TAP Committee, with seven recommended for further development as initial arms of the Pediatric MATCH trial. The current evidence for availability, efficacy, and safety of targeted agents in children for each class of mutation considered for inclusion in the Pediatric MATCH trial is discussed in this review.

Indexed as

Molecular Targeted TherapyAnaplastic Lymphoma KinaseAntineoplastic AgentsChildCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6HumansMAP Kinase Kinase KinasesNeoplasmsOncogene ProteinsPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsReceptor Protein-Tyrosine KinasesReceptors, Fibroblast Growth FactorReceptors, Platelet-Derived Growth FactorResearch DesignAnaplastic Lymphoma KinaseAntineoplastic AgentsCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6MAP Kinase Kinase KinasesMTOR protein, humanOncogene Proteinsoncogene protein trkPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsReceptor Protein-Tyrosine KinasesReceptors, Fibroblast Growth FactorReceptors, Platelet-Derived Growth FactorTOR Serine-Threonine Kinases

Identifiers

PMID28376230
PMCPMC5963793
OpenAlexW2587271093

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.